COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,785 Articles (22,523 medRxiv, 8,262 bioRxiv)

Most recent first Previous |  Page 532: Articles 5311-5320  | Next

Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated followed by an mRNA vaccine in children aged 5 - 11 years
Wanlapakorn, N., Kanokudom, S., Phowatthanasathian, H., Chansaenroj, J., Suntronwong, N., Assawakosri, S., Yorsaeng, R., Nilyanimit, P., Vichaiwattana, P., Klinfueng, S., Thongmee, T., Aeemjinda, R., Khanarat, N., Srimuan, D., Thatsanatorn, T., Sudhinaraset, N., Poovorawan, Y.
10.1101/2022.11.07.22282028 — Posted: 2022-11-10
Sentiments and Emotions for Vaccination in 2021: An International Comparison Study
Liu, X.-J.
10.1101/2022.11.04.22281946 — Posted: 2022-11-10
Outcome Of Total Surgical Debridement Of Covid Associated Skull base Mucormycosis Based on a New Surgical Staging System: Evidence From A Cohort Study.
Kurup, L. R., Singh, H., Sharma, S., Dehgani-Mobaraki, P., Zaidi, A. K., Janakiram, T. N.
10.1101/2022.11.04.22281828 — Posted: 2022-11-10
SARS-CoV-2 ORF8 limits expression levels of Spike antigen.
Kim, I.-J., Lee, Y.-h., Khalid, M. M., Zhang, Y., Ott, M., Verdin, E.
10.1101/2022.11.09.515752 — Posted: 2022-11-09
Impact of variants of concern on SARS-CoV-2 viral dynamics in non-human primates.
Marc, A., Marlin, R., Donati, F., Prague, M., Kerioui, M., Herate, C., Alexandre, M., Dereuddre-bosquet, N., Bertrand, J., Contreras, V., Behillil, S., Maisonnasse, P., Van Der Werf, S., Le Grand, R., Guedj, J.
10.1101/2022.11.09.515748 — Posted: 2022-11-09
Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
Xia, H., Yeung, J., Kalveram, B., Bills, C. J., Chen, J. Y.-C., Kurhade, C., Zou, j., Widen, S. G., Mann, B. R., Kondor, R. J., Davis, T. C., Zhou, B., Wentworth, D. E., Xie, X., Shi, P.-Y.
10.1101/2022.11.08.515725 — Posted: 2022-11-09
Bivalent BNT162b2mRNA original/Omicron BA.4-5 booster vaccination: adverse reactions and inability to work compared to the monovalent COVID-19 booster
Wagenhäuser, I., Reusch, J., Gabel, A., Krone, L. B., Kurzai, O., Petri, N., Krone, M.
10.1101/2022.11.07.22281982 — Posted: 2022-11-08
Normalized Semi-Covariance Co-Efficiency Analysis of Spike Proteins from SARS-CoV-2 variant Omicron and Other Coronaviruses for their Infectivity and Virulence
Zhang, W., Xu, T., Zhou, S., Huang, J. S.
10.1101/2022.11.07.515557 — Posted: 2022-11-08
Prediction of Transport, Deposition, and Resultant Immune Response of Nasal Spray Vaccine Droplets using a CFPD-HCD Model in a 6-Year-Old Upper Airway Geometry to Potentially Prevent COVID-19
Hayati, H., Feng, Y., Chen, X., Kolewe, E., Fromen, C.
10.1101/2022.11.08.515673 — Posted: 2022-11-08
Optimization of the Illumina COVIDSeq™ protocol for decentralized, cost-effective genomic surveillance
Carpenter, R. E., Tamrakar, V. K., Almas, S., Rowan, C., Sharma, R.
10.1101/2022.11.07.515545 — Posted: 2022-11-08

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).